BENITIONSClinical Trial Intelligence

Effect of Obesity on Proton Pump Inhibitors

4期 已完成 NCT04248335

适应症Pediatric Obesity, NAFLD, GERD
分期4期
申办方Children's Mercy Hospital Kansas City
状态已完成
受试者人数76 人
干预(药物)Lansoprazole, Pantoprazole, Midazolam
开始日期2018年7月3日
完成日期2024年12月31日
结果公布日2026年6月4日

摘要

This longitudinal study tests the hypothesis that obesity affects drug pharmacology of acid suppression medications in children.

Plasma 1/2 Life (t1/2)

samples collected at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours after ingestion of study PPI drug · hours

Lansoprazole1.23 ± 0.77 hours
Pantoprazole1.09 ± 1.03 hours

Weight-adjusted Clearance

samples collected at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours after ingestion of study PPI drug · L//kg/hr

Lansoprazole0.18 ± 0.23 L//kg/hr
Pantoprazole0.1 ± 0.06 L//kg/hr

AUC

samples collected at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours after ingestion of study PPI drug · microgram/mL*h

Lansoprazole3.4 ± 3.5 microgram/mL*h
Pantoprazole6.5 ± 7.25 microgram/mL*h

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

全部试验

本页整理自 ClinicalTrials.gov 的公开数据,不构成医疗建议,也不构成投资建议。请务必咨询专业医师。